Lipocine (NASDAQ:LPCN) was downgraded by research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research note issued on Monday, The Fly reports.
Separately, ValuEngine downgraded Lipocine from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd.
Shares of Lipocine stock traded down $1.99 during trading on Monday, reaching $0.74. The company’s stock had a trading volume of 95,323 shares, compared to its average volume of 343,640. The firm has a market cap of $70.81 million, a price-to-earnings ratio of -1.35 and a beta of 0.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.42 and a current ratio of 4.42. Lipocine has a one year low of $1.04 and a one year high of $3.45. The business’s fifty day moving average price is $2.83 and its 200-day moving average price is $2.23.
A number of large investors have recently bought and sold shares of LPCN. FNY Investment Advisers LLC acquired a new position in Lipocine during the 2nd quarter worth $27,000. BlackRock Inc. lifted its holdings in Lipocine by 17.2% during the 2nd quarter. BlackRock Inc. now owns 364,196 shares of the specialty pharmaceutical company’s stock worth $710,000 after buying an additional 53,535 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Lipocine by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 495,659 shares of the specialty pharmaceutical company’s stock worth $967,000 after buying an additional 88,959 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Lipocine by 15.7% during the 2nd quarter. Vanguard Group Inc. now owns 555,868 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after buying an additional 75,245 shares in the last quarter. 11.51% of the stock is currently owned by hedge funds and other institutional investors.
Lipocine Company Profile
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Read More: Why is cost of goods sold important?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.